Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple

Thalidomide changed the treatment of patients with multiple myeloma, however, its effectiveness has been compromised due to its side effects. New strategies are needed to specifically target the challenges of multiple myeloma through innovative, more effective, and less toxic therapy. The new immuno...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fernández-Lázaro,Diego, Fernández-Lázaro,César Ignacio, Caballero García,Alberto, Córdova Martínez,Alfredo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2018
Materias:	Dexamethasone Multiple Myeloma Neoplasm: Immunomodulation
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018001201444
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872018001201444
record_format	dspace
spelling	oai:scielo:S0034-988720180012014442019-02-18Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltipleFernández-Lázaro,DiegoFernández-Lázaro,César IgnacioCaballero García,AlbertoCórdova Martínez,Alfredo Dexamethasone Multiple Myeloma Neoplasm: Immunomodulation Thalidomide changed the treatment of patients with multiple myeloma, however, its effectiveness has been compromised due to its side effects. New strategies are needed to specifically target the challenges of multiple myeloma through innovative, more effective, and less toxic therapy. The new immunomodulatory (IMiDs) compounds are structural and functional analogs of thalidomide, which were designed to improve the immunomodulatory and anticancer properties and tolerability profiles. We review the development of second generation IMiDs, lenalidomide and pomalidomide, their immunomodulatory and tumoricidal effects, their mechanisms of action, as well as the influence of dexamethasone on their effect and pharmacological resistance. In conclusion, lenalidomide and pomalidomide demonstrate a powerful activity and they are highly effective and well-tolerated treatment options for patients with myeloma, used alone or in combination with dexamethasone.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.146 n.12 20182018-12-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018001201444es10.4067/s0034-98872018001201444
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Dexamethasone Multiple Myeloma Neoplasm: Immunomodulation
spellingShingle	Dexamethasone Multiple Myeloma Neoplasm: Immunomodulation Fernández-Lázaro,Diego Fernández-Lázaro,César Ignacio Caballero García,Alberto Córdova Martínez,Alfredo Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
description	Thalidomide changed the treatment of patients with multiple myeloma, however, its effectiveness has been compromised due to its side effects. New strategies are needed to specifically target the challenges of multiple myeloma through innovative, more effective, and less toxic therapy. The new immunomodulatory (IMiDs) compounds are structural and functional analogs of thalidomide, which were designed to improve the immunomodulatory and anticancer properties and tolerability profiles. We review the development of second generation IMiDs, lenalidomide and pomalidomide, their immunomodulatory and tumoricidal effects, their mechanisms of action, as well as the influence of dexamethasone on their effect and pharmacological resistance. In conclusion, lenalidomide and pomalidomide demonstrate a powerful activity and they are highly effective and well-tolerated treatment options for patients with myeloma, used alone or in combination with dexamethasone.
author	Fernández-Lázaro,Diego Fernández-Lázaro,César Ignacio Caballero García,Alberto Córdova Martínez,Alfredo
author_facet	Fernández-Lázaro,Diego Fernández-Lázaro,César Ignacio Caballero García,Alberto Córdova Martínez,Alfredo
author_sort	Fernández-Lázaro,Diego
title	Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
title_short	Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
title_full	Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
title_fullStr	Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
title_full_unstemmed	Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
title_sort	agentes inmunomoduladores (imids): herramientas para el tratamiento del mieloma múltiple
publisher	Sociedad Médica de Santiago
publishDate	2018
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018001201444
work_keys_str_mv	AT fernandezlazarodiego agentesinmunomoduladoresimidsherramientasparaeltratamientodelmielomamultiple AT fernandezlazarocesarignacio agentesinmunomoduladoresimidsherramientasparaeltratamientodelmielomamultiple AT caballerogarciaalberto agentesinmunomoduladoresimidsherramientasparaeltratamientodelmielomamultiple AT cordovamartinezalfredo agentesinmunomoduladoresimidsherramientasparaeltratamientodelmielomamultiple
_version_	1718437038517125120

Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple

Ejemplares similares